-transparent.png){kind=logo}
A new class of potent, selective, nonsteroidal inhibitors of aromatase have been discovered. The most potent member of this series is fadrozole hydrochloride, CGS 16949 A, 4-(5,6,7,8-tetrahydroimidazo[1,5-alpha]pyridin-5-yl)benzonitrile monohydrochloride, 26a. In addition, the 6,7-dihydropyrrolo[1,2-c]imidazole (21a) and the 6,7,8,9-tetrahydroimidazo[1,5-alpha]azepine (21b) analogues were synthesized and evaluated. CGS 16949 A's ability to selectively inhibit aromatase (IC50 = 4.5 nM) over other cytochrome P-450 enzymes and suppress estrogen production when administered orally make it a suitable candidate to test the potential of an aromatase inhibitor in estrogen-dependent diseases including breast cancer.
L J Browne, and
C Gude, and
H Rodriguez, and
R E Steele, and
A Bhatnager
November 1995,
Gan to kagaku ryoho. Cancer & chemotherapy,
L J Browne, and
C Gude, and
H Rodriguez, and
R E Steele, and
A Bhatnager
January 1999,
Cancer,
L J Browne, and
C Gude, and
H Rodriguez, and
R E Steele, and
A Bhatnager
September 1992,
The Journal of steroid biochemistry and molecular biology,
L J Browne, and
C Gude, and
H Rodriguez, and
R E Steele, and
A Bhatnager
January 1994,
European journal of cancer (Oxford, England : 1990),
L J Browne, and
C Gude, and
H Rodriguez, and
R E Steele, and
A Bhatnager
February 1996,
British journal of cancer,
L J Browne, and
C Gude, and
H Rodriguez, and
R E Steele, and
A Bhatnager
June 1992,
Hormones and behavior,
L J Browne, and
C Gude, and
H Rodriguez, and
R E Steele, and
A Bhatnager
April 1994,
General and comparative endocrinology,
L J Browne, and
C Gude, and
H Rodriguez, and
R E Steele, and
A Bhatnager
November 1997,
Oncology (Williston Park, N.Y.),
L J Browne, and
C Gude, and
H Rodriguez, and
R E Steele, and
A Bhatnager
July 1991,
The Journal of clinical endocrinology and metabolism,
L J Browne, and
C Gude, and
H Rodriguez, and
R E Steele, and
A Bhatnager
January 1987,
Steroids,
